Cargando…

Early Adoption of Checkpoint Inhibitors in Patients with Metastatic Gastric Adenocarcinoma—A Case Series of Non-Operative Long-Term Survivors

Checkpoint inhibitor (CPI) therapy has only recently been introduced in the first-line treatment of advanced gastric cancer. However, later line monotherapy CPI efficacy in a subset of patients was presented about four years prior. Here, we present three cases of advanced gastric adenocarcinoma canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaakour, Dalia, Ward, Garrett, Dayyani, Farshid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149843/
https://www.ncbi.nlm.nih.gov/pubmed/35645245
http://dx.doi.org/10.3390/diseases10020024
_version_ 1784717290484269056
author Kaakour, Dalia
Ward, Garrett
Dayyani, Farshid
author_facet Kaakour, Dalia
Ward, Garrett
Dayyani, Farshid
author_sort Kaakour, Dalia
collection PubMed
description Checkpoint inhibitor (CPI) therapy has only recently been introduced in the first-line treatment of advanced gastric cancer. However, later line monotherapy CPI efficacy in a subset of patients was presented about four years prior. Here, we present three cases of advanced gastric adenocarcinoma cancers treated with CPI in early lines years prior to the availability of randomized first line data. All three patients remain in remission without gastrectomy, with the median time from initial diagnosis of approximately 52 months. With long-term follow-up of more than four years, we present a proof of concept that, with early integration of CPI therapy, highly durable responses are possible even in the absence of surgery in patients with advanced gastric and gastroesophageal junction cancers.
format Online
Article
Text
id pubmed-9149843
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91498432022-05-31 Early Adoption of Checkpoint Inhibitors in Patients with Metastatic Gastric Adenocarcinoma—A Case Series of Non-Operative Long-Term Survivors Kaakour, Dalia Ward, Garrett Dayyani, Farshid Diseases Brief Report Checkpoint inhibitor (CPI) therapy has only recently been introduced in the first-line treatment of advanced gastric cancer. However, later line monotherapy CPI efficacy in a subset of patients was presented about four years prior. Here, we present three cases of advanced gastric adenocarcinoma cancers treated with CPI in early lines years prior to the availability of randomized first line data. All three patients remain in remission without gastrectomy, with the median time from initial diagnosis of approximately 52 months. With long-term follow-up of more than four years, we present a proof of concept that, with early integration of CPI therapy, highly durable responses are possible even in the absence of surgery in patients with advanced gastric and gastroesophageal junction cancers. MDPI 2022-04-24 /pmc/articles/PMC9149843/ /pubmed/35645245 http://dx.doi.org/10.3390/diseases10020024 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Kaakour, Dalia
Ward, Garrett
Dayyani, Farshid
Early Adoption of Checkpoint Inhibitors in Patients with Metastatic Gastric Adenocarcinoma—A Case Series of Non-Operative Long-Term Survivors
title Early Adoption of Checkpoint Inhibitors in Patients with Metastatic Gastric Adenocarcinoma—A Case Series of Non-Operative Long-Term Survivors
title_full Early Adoption of Checkpoint Inhibitors in Patients with Metastatic Gastric Adenocarcinoma—A Case Series of Non-Operative Long-Term Survivors
title_fullStr Early Adoption of Checkpoint Inhibitors in Patients with Metastatic Gastric Adenocarcinoma—A Case Series of Non-Operative Long-Term Survivors
title_full_unstemmed Early Adoption of Checkpoint Inhibitors in Patients with Metastatic Gastric Adenocarcinoma—A Case Series of Non-Operative Long-Term Survivors
title_short Early Adoption of Checkpoint Inhibitors in Patients with Metastatic Gastric Adenocarcinoma—A Case Series of Non-Operative Long-Term Survivors
title_sort early adoption of checkpoint inhibitors in patients with metastatic gastric adenocarcinoma—a case series of non-operative long-term survivors
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149843/
https://www.ncbi.nlm.nih.gov/pubmed/35645245
http://dx.doi.org/10.3390/diseases10020024
work_keys_str_mv AT kaakourdalia earlyadoptionofcheckpointinhibitorsinpatientswithmetastaticgastricadenocarcinomaacaseseriesofnonoperativelongtermsurvivors
AT wardgarrett earlyadoptionofcheckpointinhibitorsinpatientswithmetastaticgastricadenocarcinomaacaseseriesofnonoperativelongtermsurvivors
AT dayyanifarshid earlyadoptionofcheckpointinhibitorsinpatientswithmetastaticgastricadenocarcinomaacaseseriesofnonoperativelongtermsurvivors